12:11 PM
Nov 26, 2018
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Adenocarcinoma; brain cancer; lung cancer; neuroendocrine tumors

Cell culture studies identified a nicotonic acetylcholine receptor α7 (CHRNA7) antagonist that could help treat glioblastoma, lung adenocarcinoma and neuroblastoma. Chemical synthesis and cell-based testing of structural hybrids of a stilbene-based...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >